‘Surprisingly high’ remission rates for both ustekinumab, adalimumab in Crohn’s patients
Ustekinumab and adalimumab demonstrated equally high rates of clinical remission in biologic-naïve patients with moderate to severe Crohn’s disease through 1 year of treatment, according…